TapewireFind a company

person · Reporting owner

Kelly Paul Edward

Disclosed activity across 1 company

Tapewire entity
71428
SEC CIK
0001658544

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
RELMADA THERAPEUTICS, INC.RLMD · Entity 5498Director · COODecember 12, 2025December 16, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

RELMADA THERAPEUTICS, INC.

Report date December 12, 2025 · Filed December 16, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12Direct828,000 Reported balance After 2025-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-12-12 · Grant · Acquired 828,000 · Balance 828,000

F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 12, 2025 Filed Dec 16, 2025 09:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Appreciation Rights · Derivative 828,000 $0.00 Strike: $4.06 $0.00
Disclosure

SEC source: 0001213900-25-121968 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 828,000

Underlying: Common Stock · 828,000 shares

Expires 2035-12-12

F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 07:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 90,000 $2.20 $198,000.00
Disclosure

SEC source: 0001213900-25-106835 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 502,295

Read SEC document
June 26, 2025 Filed Jun 30, 2025 19:27 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 400,000 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001213900-25-059864 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2035-06-26

F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025.

Read SEC document
May 16, 2025 Filed May 20, 2025 18:03 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 200,000 $0.43 $86,060.00
Disclosure

SEC source: 0001213900-25-046088 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 412,295

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $0.4071 to $0.4498 per share, inclusive.

Read SEC document
September 09, 2024 Filed Sep 11, 2024 17:46 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 25,000 $2.59 $64,750.00
Disclosure

SEC source: 0001213900-24-077791 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,295

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $2.50 to $2.64 per share, inclusive.

Read SEC document
May 24, 2024 Filed May 29, 2024 21:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 OtherStock Option (right to buy) · Derivative 43,700 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047637 · ownership.xml · derivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,672

Underlying: Common Stock · 43,700 shares

Expires 2033-12-15

F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.

Read SEC document
May 24, 2024 Filed May 29, 2024 21:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 43,700 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047637 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,372

Underlying: Common Stock · 43,700 shares

Expires 2033-12-15

F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 43,700 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares.

Read SEC document
December 15, 2023 Filed Dec 19, 2023 17:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 65,672 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-23-097029 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,672

Underlying: Common Stock · 65,672 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 15, 2024.

Read SEC document
May 25, 2023 Filed May 30, 2023 17:08 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 92,958 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-23-044087 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 92,958 shares

Expires 2032-12-16

F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 17:32 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 57,042 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-22-081477 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,042

Underlying: Common Stock · 57,042 shares

Expires 2032-12-16

F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
May 25, 2022 Filed May 26, 2022 18:43 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 182,470 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-22-029838 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 182,470 shares

Expires 2031-12-17

F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.

Read SEC document
April 04, 2022 Filed Apr 5, 2022 17:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 10,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-22-018223 · ownership.xml · derivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 10,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
April 04, 2022 Filed Apr 5, 2022 17:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 10,000 $30.04 $300,395.00
Disclosure

SEC source: 0001213900-22-018223 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $30.00 to $30.20 per share, inclusive.

Read SEC document
April 04, 2022 Filed Apr 5, 2022 17:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 10,000 $3.24 $32,400.00
Disclosure

SEC source: 0001213900-22-018223 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:01 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 20,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-22-000761 · ownership.xml · derivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,500

Underlying: Common Stock · 20,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:01 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 20,000 $3.24 $64,800.00
Disclosure

SEC source: 0001213900-22-000761 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 17, 2021 Filed Dec 21, 2021 21:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 117,530 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-21-066821 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,530

Underlying: Common Stock · 117,530 shares

Expires 2031-12-17

F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022.

Read SEC document
July 08, 2021 Filed Feb 2, 2023 17:00 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GiftStock Option (right to buy) · Derivative 18,000 $0.00 Strike: $33.43 $0.00
Disclosure

SEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,000

Underlying: Common Stock · 18,000 shares

Expires 2031-01-07

F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust.

F5 · derivative.exercise_date: The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant.

Read SEC document
July 08, 2021 Filed Feb 2, 2023 17:00 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GiftStock Option (right to buy) · Derivative 56,000 $0.00 Strike: $43.47 $0.00
Disclosure

SEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,000

Underlying: Common Stock · 56,000 shares

Expires 2029-12-19

F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust.

F4 · derivative.exercise_date: The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant.

Read SEC document
July 08, 2021 Filed Feb 2, 2023 17:00 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GiftStock Option (right to buy) · Derivative 19,600 $0.00 Strike: $8.80 $0.00
Disclosure

SEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,400

Underlying: Common Stock · 19,600 shares

Expires 2029-07-29

F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust.

F3 · derivative.exercise_date: The options were granted on July 29, 2019. 6.25% of the options vest each quarter from the date of grant.

Read SEC document
July 08, 2021 Filed Feb 2, 2023 17:00 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GiftStock Option (right to buy) · Derivative 6,400 $0.00 Strike: $13.80 $0.00
Disclosure

SEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41

Underlying: Common Stock · 4,800 shares

Expires 2025-11-12

F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust.

F2 · derivative.exercise_date: The options were granted on November 12, 2015. 25% of the options vested one year from the grant date and the remaining 75% of the options vested in equal quarterly increments of 6.25% of the initial option grant over the following three year period.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 17:50 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 5,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-014917 · ownership.xml · derivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,500

Underlying: Common Stock · 5,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable.

F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 17:50 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,612 $36.33 $58,556.06
Disclosure

SEC source: 0001213900-21-014917 · ownership.xml · nonDerivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $36.07 to $36.55 per share, inclusive.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 17:50 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 3,388 $35.42 $119,994.83
Disclosure

SEC source: 0001213900-21-014917 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,907

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.00 to $35.94 per share, inclusive.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 17:50 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 5,000 $3.24 $16,200.00
Disclosure

SEC source: 0001213900-21-014917 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:49 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 108 $35.58 $3,842.92
Disclosure

SEC source: 0001213900-21-012171 · ownership.xml · nonDerivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $35.49 to $35.59 per share, inclusive.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:49 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,463 $34.64 $85,315.12
Disclosure

SEC source: 0001213900-21-012171 · ownership.xml · nonDerivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,403

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $34.29 to $35.15 per share, inclusive.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:49 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,429 $33.67 $81,774.96
Disclosure

SEC source: 0001213900-21-012171 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,866

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $33.29 to $34.28 per share, inclusive.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:49 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 5,000 $3.24 $16,200.00
Disclosure

SEC source: 0001213900-21-012171 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 16, 2021 Filed Feb 17, 2021 18:37 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionWarrants · Derivative 5,000 $6.00 Strike: $6.00 $30,000.00
Disclosure

SEC source: 0001213900-21-010148 · ownership.xml · derivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 5,000 shares

Expires 2024-10-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: This Warrant was previously reported as covering 100,000 shares of common stock at an exercise price of $1.50 per share, but was adjusted to reflect the stock split that occurred on September 30, 2019.

F1 · balance_after: This Warrant was previously reported as covering 100,000 shares of common stock at an exercise price of $1.50 per share, but was adjusted to reflect the stock split that occurred on September 30, 2019.

Read SEC document
February 16, 2021 Filed Feb 17, 2021 18:37 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 5,000 $6.00 $30,000.00
Disclosure

SEC source: 0001213900-21-010148 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 09, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,069 $35.29 $73,004.67
Disclosure

SEC source: 0001213900-21-008203 · ownership.xml · nonDerivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $35.03 to $35.79 per share, inclusive.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 3,569 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-008203 · ownership.xml · derivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,500

Underlying: Common Stock · 3,569 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable.

F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,500 $35.04 $52,559.85
Disclosure

SEC source: 0001213900-21-008203 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,364

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.00 to $35.17 per share, inclusive.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 3,569 $3.24 $11,563.56
Disclosure

SEC source: 0001213900-21-008203 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 08, 2021 Filed Feb 26, 2021 16:49 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 5,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-012171 · ownership.xml · derivative · entry 5

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,500

Underlying: Common Stock · 5,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable.

F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 02, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,315 $35.04 $81,117.60
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · nonDerivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.00 to $35.29 per share, inclusive.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 2,346 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · derivative · entry 6

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,069

Underlying: Common Stock · 2,346 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 15,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · derivative · entry 5

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,415

Underlying: Common Stock · 15,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 31 $35.00 $1,085.00
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · nonDerivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,610

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 2,346 $3.24 $7,601.04
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,641

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 15,000 $3.24 $48,600.00
Disclosure

SEC source: 0001213900-21-006570 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:20 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 5,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-005443 · ownership.xml · derivative · entry 5

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,415

Underlying: Common Stock · 5,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable.

F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:20 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 168 $33.40 $5,611.20
Disclosure

SEC source: 0001213900-21-005443 · ownership.xml · nonDerivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $33.39 to $33.45 per share, inclusive.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:20 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,988 $32.89 $98,275.32
Disclosure

SEC source: 0001213900-21-005443 · ownership.xml · nonDerivative · entry 3

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,463

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $32.39 to $33.38 per share, inclusive.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:20 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,844 $31.69 $58,436.36
Disclosure

SEC source: 0001213900-21-005443 · ownership.xml · nonDerivative · entry 2

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,451

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $31.30 to $32.29 per share, inclusive.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:20 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 5,000 $3.24 $16,200.00
Disclosure

SEC source: 0001213900-21-005443 · ownership.xml · nonDerivative · entry 1

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 26, 2021 Filed Jan 26, 2021 19:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 685 $35.16 $24,084.60
Disclosure

SEC source: 0001213900-21-004482 · ownership.xml · nonDerivative · entry 5

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,295

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $35.00 to $35.75 per share, inclusive.

Read SEC document
January 25, 2021 Filed Jan 26, 2021 19:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,300 $35.27 $45,851.00
Disclosure

SEC source: 0001213900-21-004482 · ownership.xml · nonDerivative · entry 4

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,980

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $35.00 to $35.51 per share, inclusive.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 19:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 4,085 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-004482 · ownership.xml · derivative · entry 6

Kelly Paul Edward · CIK 0001658544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,415

Underlying: Common Stock · 3,400 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: Not applicable.

F7 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.